Baxter Ventures will invest $200M in early-stage companies
Baxter International (NYSE:BAX) put aside $200M in equity to invest in early-stage companies that “complement” its portfolio.
- The newly established, Baxter Ventures will invest “globally and focus on innovative technologies with sustainable long-term growth” under the watch of CSO, Norbert Riedel.
The Bottom Line: The news comes as med-tech companies are facing increasing competition from private equity firms with renewed interest in medical device acquisitions. Baxter Ventures will provide BAX access to promising, early-stage technologies with their capital and expertise. Through these investments, BAX can expand its internal pipeline and medical therapies.
Related Posts
Categories: Baxter Ventures, Venture Financing
